雄激素受体与肝细胞肝癌预后的关系  

Androgen recepter as a prognostic factor of hepatocellular carcinoma

作　　者：贺青卿[1] 杨金镛[2] 吴力群[2] 崔自介[2] 

机构地区：[1]济南军区总医院普外科,济南250031 [2]青岛医学院附属医院普外科

出　　处：《胃肠病学和肝病学杂志》1999年第3期209-210,共2页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的　探讨雄激素受体（ＡＲ） 与肝细胞肝癌（ ＨＣＣ） 的关系。方法　用葡聚糖包裹活性炭饱和吸附法检测４７例ＨＣＣ 癌组织和癌旁肝组织中ＡＲ 的含量。对４３ 例病人进行术后随访９ ～６０ 个月。结果　３３ 例ＡＲ 阳性（３－０ ～１００ｆｍｏｌ／ｍｇ 蛋白） ，１４ 例ＡＲ 阴性。ＡＲ 阳性病人与ＡＲ 阴性病人的一、五年存活率没有统计学差别（ Ｐ＞ ０－０５） ，三年存活率ＡＲ 阳性者（３５－５ ％ ） 显著低于ＡＲ 阴性者（６６－７ ％ ）（ Ｐ＜ ０－０５） 。复发时间ＡＲ 阳性者（２１－４ ±１５－２ 月） 与ＡＲ 阴性者（３３－９±１３－９ 月） 有显著差异（ Ｐ＜ ０－０５） 。结论　雄激素能促进ＨＣＣ 的增长及对周围组织的侵袭，部分ＨＣＣ 具有雄激素依赖性，ＡＲ 可作为ＨＣＣAim Studying androgen receptor(AR) in hepatocellular carcinoma (HCC)as a prognostic factor after hepatic resection.Method ARs in the cytosol of HCC were assayed by dextran-coated charcoal method in 47 patients in whom radical hepatic resection was performed.43 patients were followed up for 9-60 months.Results 33 patients had detectable amounts of ARs(ranging from 3.0 to 100fmol/mg protein).The receptor was not found in 14 cases.The 1-year and 5-year survival rate in the AR positive and AR negative groups were not statistically significant ( P >0 05) The 3-year survival rate was significantly better( P <0 05) in the AR negative group(66.7%) than that of AR positive group(35.5%).There were significantly difference in the recurrence time between patients with AR negative HCCs(33 9±13 9months)and those with AR positive tumors(21.4±15.2months) Conclusions Testosterone enhances the growth and invasion of human HCC,which is mediated by AR in the tumor.AR acts as a prognostic factor after hepatic resection.

关 键 词：肝肿瘤 雄激素 受体 预后 

分 类 号：R735.707[医药卫生—肿瘤]